Skye Bioscience, Inc. (SKYE)
USD 3.01
(-7.38%)
USD 3.01
(-7.38%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -13.67 Million USD | 25.34% |
| 2022 | -18.31 Million USD | -133.34% |
| 2021 | -7.84 Million USD | -24.78% |
| 2020 | -6.28 Million USD | 5.18% |
| 2019 | -6.63 Million USD | -41.34% |
| 2018 | -4.69 Million USD | -21.59% |
| 2017 | -3.85 Million USD | 13.67% |
| 2016 | -4.47 Million USD | -3.55% |
| 2015 | -4.31 Million USD | -58.04% |
| 2014 | -2.73 Million USD | -2168.76% |
| 2013 | -120.4 Thousand USD | -3024.53% |
| 2012 | 4117.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -6.15 Million USD | -50.56% |
| 2024 Q2 | -8.4 Million USD | -36.63% |
| 2023 Q2 | -2.84 Million USD | 8.3% |
| 2023 Q1 | -3.1 Million USD | 66.6% |
| 2023 Q4 | -4.08 Million USD | 83.46% |
| 2023 FY | -13.67 Million USD | 25.34% |
| 2023 Q3 | -24.7 Million USD | -769.0% |
| 2022 Q4 | -9.28 Million USD | -217.67% |
| 2022 Q1 | -2.88 Million USD | -17.32% |
| 2022 Q2 | -3.21 Million USD | -11.44% |
| 2022 Q3 | -2.92 Million USD | 9.2% |
| 2022 FY | -18.31 Million USD | -133.34% |
| 2021 Q3 | -1.81 Million USD | 0.58% |
| 2021 Q4 | -2.46 Million USD | -35.32% |
| 2021 Q2 | -1.82 Million USD | -5.32% |
| 2021 Q1 | -1.73 Million USD | -31.72% |
| 2021 FY | -7.84 Million USD | -24.78% |
| 2020 FY | -6.28 Million USD | 5.18% |
| 2020 Q3 | -1.53 Million USD | -26.02% |
| 2020 Q2 | -1.22 Million USD | 44.8% |
| 2020 Q4 | -1.31 Million USD | 14.26% |
| 2020 Q1 | -2.21 Million USD | -19.95% |
| 2019 Q3 | -1.5 Million USD | 15.12% |
| 2019 FY | -6.63 Million USD | -41.34% |
| 2019 Q2 | -1.77 Million USD | -16.89% |
| 2019 Q4 | -1.84 Million USD | -22.65% |
| 2019 Q1 | -1.51 Million USD | -15.18% |
| 2018 FY | -4.69 Million USD | -21.59% |
| 2018 Q4 | -1.31 Million USD | -25.8% |
| 2018 Q3 | -1.04 Million USD | 3.2% |
| 2018 Q2 | -1.08 Million USD | 13.68% |
| 2018 Q1 | -1.25 Million USD | -26.85% |
| 2017 FY | -3.85 Million USD | 13.67% |
| 2017 Q4 | -986.51 Thousand USD | -29.53% |
| 2017 Q1 | -1.38 Million USD | -51.32% |
| 2017 Q2 | -730.92 Thousand USD | 47.04% |
| 2017 Q3 | -761.63 Thousand USD | -4.2% |
| 2016 Q2 | -1.48 Million USD | -21.44% |
| 2016 FY | -4.47 Million USD | -3.55% |
| 2016 Q3 | -856.14 Thousand USD | 42.23% |
| 2016 Q4 | -912.05 Thousand USD | -6.53% |
| 2016 Q1 | -1.22 Million USD | -5.71% |
| 2015 FY | -4.31 Million USD | -58.04% |
| 2015 Q3 | -896.29 Thousand USD | 33.93% |
| 2015 Q4 | -1.15 Million USD | -28.8% |
| 2015 Q2 | -1.35 Million USD | -49.1% |
| 2015 Q1 | -909.82 Thousand USD | 46.51% |
| 2014 Q4 | -1.7 Million USD | -98.34% |
| 2014 Q3 | -857.61 Thousand USD | -21265.18% |
| 2014 Q2 | 4052.00 USD | 130.17% |
| 2014 Q1 | -13.43 Thousand USD | -991.95% |
| 2014 FY | -2.73 Million USD | -2168.76% |
| 2013 Q1 | 3612.00 USD | 158.31% |
| 2013 Q2 | 744.00 USD | -79.4% |
| 2013 Q3 | -5274.00 USD | -808.87% |
| 2013 Q4 | -1230.00 USD | 76.68% |
| 2013 FY | -120.4 Thousand USD | -3024.53% |
| 2012 FY | 4117.00 USD | 0.0% |
| 2012 Q1 | -550.00 USD | 0.0% |
| 2012 Q2 | -93.00 USD | 83.09% |
| 2012 Q3 | 4760.00 USD | 5218.28% |
| 2012 Q4 | -6194.00 USD | -230.13% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HST Global, Inc. | -140.9 Thousand USD | -9602.712% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1890.218% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -7871.452% |
| CytoDyn Inc. | -18.05 Million USD | 24.29% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 76.824% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| MultiCell Technologies, Inc. | -722.81 USD | -1891379.089% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -652.72% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -171.025% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -45545.7% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -7433.295% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Alpha Cognition Inc. | -9.7 Million USD | -40.865% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 75.37% |
| SQZ Biotechnologies Company | -75.82 Million USD | 81.969% |
| Resverlogix Corp. | -12.74 Million USD | -7.238% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -3409.459% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 240.332% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -456.824% |
| Mesoblast Limited | -84.14 Million USD | 83.752% |
| GB Sciences, Inc. | -1.42 Million USD | -862.458% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1890.218% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 23.394% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -301.524% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -105.652% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -331.522% |
| ContraFect Corporation | -56.88 Million USD | 75.968% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -397.005% |
| BioStem Technologies, Inc. | -7.77 Million USD | -75.753% |
| LadRx Corporation | -3.82 Million USD | -257.561% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 13.85% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1121.787% |
| CSL Limited | 3.7 Billion USD | 100.369% |
| Biomind Labs Inc. | -1 Million USD | -1254.176% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -1367.908% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 116.703% |
| Nascent Biotech, Inc. | -2.22 Million USD | -513.118% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 80.955% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 378.175% |
| GeneThera, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 486.209% |
| Adynxx, Inc. | - USD | Infinity% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -790.063% |
| Marizyme, Inc. | -34.08 Million USD | 59.891% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -63.734% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -2320.975% |
| Zenith Capital Corp. | -8.94 Million USD | -52.877% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -379.627% |
| Halberd Corporation | -75.05 Thousand USD | -18116.922% |
| Genus plc | 6.4 Million USD | 313.622% |
| Pharming Group N.V. | -4.87 Million USD | -180.186% |
| MetaStat, Inc. | - USD | Infinity% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -588.243% |
| IMV Inc. | -38.67 Million USD | 64.646% |
| Affymax, Inc. | -15.04 Million USD | 9.133% |
| SYBLEU INC | -149.18 Thousand USD | -9064.633% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -1209.559% |
| Enzolytics Inc. | -2.14 Million USD | -536.253% |
| argenx SE | -425.04 Million USD | 96.783% |
| AVAX Technologies, Inc. | 6.69 Million USD | 304.274% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -875.17% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -923.774% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -264.93% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -54217.839% |
| Cell Source, Inc. | -4.32 Million USD | -216.086% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -2730.237% |
| Q BioMed Inc. | -3.44 Million USD | -296.788% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -222.569% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -988.519% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -420.331% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -200.167% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 75.13% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -371.238% |
| Rebus Holdings, Inc. | -664 Thousand USD | -1959.006% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -1289.336% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -633.32% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -581.968% |
| ONE Bio Corp. | 13.68 Million USD | 199.929% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -607.427% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -1115.373% |
| Agentix Corp. | -1.37 Million USD | -896.664% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -368.301% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -765.657% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -78378.847% |
| Kadimastem Ltd | -3.04 Million USD | -349.693% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -5123.707% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -3190.612% |
| NovAccess Global Inc. | -2.46 Million USD | -454.241% |
| Itoco Inc. | -919.14 Thousand USD | -1387.456% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -6112.252% |
| Qrons Inc. | -643.67 Thousand USD | -2024.016% |
| Mobile Lads Corp. | -554.55 Thousand USD | -2365.386% |
| Genscript Biotech Corporation | -415.79 Million USD | 96.712% |
| International Stem Cell Corporation | -663 Thousand USD | -1962.112% |
| Bioxytran, Inc. | -3.82 Million USD | -257.887% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -25872.264% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -67116.323% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 62.301% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -744.981% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -1757.998% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -339.466% |
| Neutra Corp. | -229.48 Thousand USD | -5857.575% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 22.049% |
| PureTech Health plc | -146.19 Million USD | 90.648% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 36.384% |
| IXICO plc | -1.43 Million USD | -851.413% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -44.05% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 88.776% |
| CSL Limited | 3.81 Billion USD | 100.359% |
| Cellectis S.A. | -108.85 Million USD | 87.441% |